Abstract
Photodynamic therapy (PDT) has become a standard, routine procedure in dermatology over the past several years. Most clinicians have found that by utilizing PDT, many dermatologic conditions can be successfully treated. This article will review the experience with aminolevulinic acid (Levulan®) PDT, including the clinical trials that led to US FDA approval for the treatment of nonhyperkeratotic actinic keratoses of the face or scalp and other studies showing its versatility in the treatment of various dermatologic diseases. Finally, best practice guidelines for utilizing aminolevulinic acid PDT in the clinic will be proposed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
